AnaptysBio, Inc. Common Stock (ANAB)

Price$50.37

Value ScoreD

Growth ScoreB

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)73.46%

Price vs S&P 500 (4W)-27.34%

VGM Score58.59

Market Capitalization$1.47B

All Metrics

P/CF (Annual)74.42x

Book Value / Share (Quarterly)$0.44

P/TBV (Annual)1.45x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)183.56%

Cash Flow / Share (Quarterly)$0.15

Price vs S&P 500 (YTD)47.69%

Net Profit Margin (TTM)-11.53%

EPS (TTM)$-0.88

10-Day Avg Trading Volume0.61M

EPS Excl Extra (TTM)$-0.88

Revenue Growth (5Y)25.62%

EPS (Annual)$-0.46

ROI (Annual)-4.22%

Net Profit Margin (5Y Avg)-492.16%

Cash / Share (Quarterly)$9.87

Revenue Growth QoQ (YoY)-7.98%

ROA (Last FY)-3.63%

Revenue Growth TTM (YoY)107.73%

EBITD / Share (TTM)$1.45

ROE (5Y Avg)-98.31%

Operating Margin (TTM)17.56%

Cash Flow / Share (Annual)$0.70

P/B Ratio114.99x

P/B Ratio (Quarterly)125.08x

Net Income / Employee (Annual)$-127,200

EV / Revenue (TTM)6.37x

Net Interest Coverage (TTM)-199.47x

ROA (TTM)-7.75%

EV / EBITDA (TTM)35.83x

EPS Incl Extra (Annual)$-0.46

Current Ratio (Annual)9.07x

Quick Ratio (Quarterly)7.49x

3-Month Avg Trading Volume0.78M

52-Week Price Return257.49%

EV / Free Cash Flow (Annual)75.53x

Revenue / Employee (TTM)$2,234,500

Tangible BV / Share (Quarterly)$4.53

P/S Ratio (Annual)6.25x

Asset Turnover (Annual)0.64x

52-Week High$72.36

Operating Margin (5Y Avg)-454.55%

EPS Excl Extra (Annual)$-0.46

CapEx CAGR (5Y)-31.34%

Tangible BV CAGR (5Y)-3.15%

26-Week Price Return81.38%

Quick Ratio (Annual)8.94x

13-Week Price Return31.89%

Total Debt / Equity (Annual)7.43x

Current Ratio (Quarterly)7.58x

Enterprise Value$1.48B

Revenue / Share Growth (5Y)24.32%

Asset Turnover (TTM)0.67x

Book Value / Share Growth (5Y)-37.99%

Revenue / Employee (Annual)$2,255,800

Pretax Margin (Annual)-5.57%

Cash / Share (Annual)$11.12

3-Month Return Std Dev72.66%

Net Income / Employee (TTM)$-257,600

EBITDA Interim CAGR (5Y)7.21%

ROE (Last FY)-35.56%

Net Interest Coverage (Annual)-18.43x

EPS Basic Excl Extra (Annual)$-0.46

P/FCF (TTM)14.96x

Receivables Turnover (TTM)6.73x

EV / Free Cash Flow (TTM)335.92x

Total Debt / Equity (Quarterly)20.69x

EPS Incl Extra (TTM)$-0.88

Receivables Turnover (Annual)8.96x

ROI (TTM)-1.11%

P/S Ratio (TTM)6.31x

Pretax Margin (5Y Avg)-492.11%

Revenue / Share (Annual)$8.16

Tangible BV / Share (Annual)$9.19

Price vs S&P 500 (52W)233.12%

Year-to-Date Return55.85%

5-Day Price Return-5.21%

EPS Normalized (Annual)$-0.46

ROA (5Y Avg)-19.98%

Net Profit Margin (Annual)-5.64%

Month-to-Date Return-9.52%

Cash Flow / Share (TTM)$-5.37

EBITD / Share (Annual)$1.68

Operating Margin (Annual)20.42%

LT Debt / Equity (Annual)7.43x

P/CF (TTM)327.34x

ROI (5Y Avg)-28.96%

LT Debt / Equity (Quarterly)20.69x

EPS Basic Excl Extra (TTM)$-0.88

P/TBV (Quarterly)3.15x

P/B Ratio (Annual)36.07x

Pretax Margin (TTM)-11.46%

Book Value / Share (Annual)$1.33

Price vs S&P 500 (13W)23.64%

Beta0.89x

P/FCF (Annual)74.75x

Revenue / Share (TTM)$8.10

ROE (TTM)-13.09%

52-Week Low$11.40

vGradeD

gGradeB

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-1.84est. -0.62

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.26

4.22

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ANABAnaptysBio, Inc. Common Stock	D	B	A	$50.37
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

AnaptysBio Inc develops immune cell-modulating antibody therapies for inflammatory and autoimmune diseases. The company's lead program, rosnilimab, a PD-1 agonist, is in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis. It is also developing ANB032, a BTLA agonist in Phase 2b testing for atopic dermatitis.